Article
KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2008
Tabone-Eglinger Séverine, Subra Frédéric, El Sayadi Hiba, Alberti Laurent, Tabone Eric, Michot Jean-Philippe, Théou-Anton Nathalie, Lemoine Antoinette, Blay Jean-Yves, Emile Jean-François
Abstract excerpt
PURPOSE: Gastrointestinal stromal tumors (GIST) are frequently associated with gain-of-function mutations of KIT, which can be inhibited by imatinib both in vitro and in vivo. The survival of patients with GIST, following imatinib therapy, has been correlated with the nature of mutations but not with KIT expression. EXPERIMENTAL DESIGN: Subcellular localization, activation, and trafficking of the mature and the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.